IL25 and colorectal carcinoma: Therapeutic blockade of the IL-25-ILC2 axis may be beneficial in CRC patients where APC-mutation predominates (80% of all CRC) and should be explored, but possibly not in the rarer and mutationally distinct non-APC-mutation-initiated CRCs and CAC subtypes where IL-25 may instead suppress tumorigenesis (56).